PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study

OXFORD – 10 MARCH 2016 PsiOxus Therapeutics Ltd. (PsiOxus), the immunooncology company, today announced the first treatment of a patient to combine paclitaxel with the oncolytic virotherapy enadenotucirev in the… read more →